Welcome to our dedicated page for GXII news (Ticker: GXII), a resource for investors and traders seeking the latest updates and insights on GXII stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GXII's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GXII's position in the market.
GX Acquisition Corp. II (NASDAQ: GXII) announced it will not pursue an extension for completing its initial business combination, resulting in the cancellation of the special stockholder meeting originally scheduled for March 20, 2023. This decision follows the successful approval of its business combination with NioCorp Developments Ltd. on March 15, 2023. The merger was completed on March 17, 2023, marking a significant milestone for GXII. Shareholders had previously voted on this transaction, indicating support for the strategic partnership and future endeavors.
GX Acquisition Corp. II (NASDAQ: GXIIU) received a notice from Nasdaq for failing to timely file its Quarterly Report on Form 10-Q for Q1 2021. The notice indicates non-compliance with Nasdaq’s listing requirements. The company had previously submitted a Form 12b-25, stating it was unable to meet the deadline due to changes in accounting for outstanding warrants. GXIIU has a 60-day period from the notice date (May 28, 2021) to regain compliance by filing the Form 10-Q. Failure to comply may lead to delisting procedures.
GX Acquisition Corp. II (Nasdaq: GXIIU) will allow the separation of its 30 million units sold in its IPO starting May 10, 2021. Holders can trade Class A common stock and warrants under the symbols GXII and GXIIW, respectively, while units will continue to trade as GXIIU. No fractional warrants will be issued. A registration statement was effective as of March 17, 2021. The company is a blank check entity focused on acquiring businesses with an enterprise value exceeding $1 billion.
GX Acquisition Corp. II has successfully closed its initial public offering of 30 million units at $10.00 each. The units are now listed on Nasdaq under the symbol ‘GXIIU’ and each consists of one Class A share plus one-third of a redeemable warrant, which can be exercised at $11.50. The company aims to pursue a business combination with targets having an enterprise value of over $1 billion. Cantor Fitzgerald served as the sole book-running manager and has a 45-day option for an additional 4.5 million units.
GX Acquisition Corp. II announced the pricing of its initial public offering (IPO) of 30,000,000 units at $10.00 each, set to begin trading on Nasdaq under the ticker symbol “GXIIU” on March 18, 2021. Each unit comprises one share of Class A common stock and one-third of a redeemable warrant. The company seeks to acquire businesses with an enterprise value exceeding $1 billion. Cantor Fitzgerald & Co. is the sole book runner for the offering, which includes a 45-day overallotment option for underwriters to purchase an additional 4,500,000 units.
FAQ
What is the market cap of GXII (GXII)?
